Browsing by Author Paré, Laia
Showing results 10 to 19 of 19
< previous
Issue Date | Title | Author(s) |
---|---|---|
24-Sep-2014 | Large differences in global transcriptional regulatory programs of normal and tumor colon cells | Cordero Romera, David; Solé Acha, Xavier; Crous Bou, Marta; Sanz Pamplona, Rebeca; Paré, Laia; Guinó, Elisabet; Olivares, David; Berenguer, Antoni; Santos, Cristina; Salazar Soler, Ramón; Biondo, Sebastián; Moreno Aguado, Víctor |
28-Mar-2017 | Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer | Fernández Martínez, Aranzazu; Pascual, Tomás; Perrone, Giuseppe; Morales, Serafín; Haba, Juan de la; González Rivera, Milagros; Galván, Patricia; Zalfa, Francesca; Amato, Michela; Gonzalez, Lucía; Prats de Puig, Miquel; Rojo, Federico; Manso, Luis; Paré, Laia; Alonso, Immaculada; Albanell Mestres, Joan; Vivancos, Ana; González, Antonio; Matito, Judit; González, Sonia; Fernández Ruiz, Pedro Luis; Adamo, Barbara; Muñoz Mateu, Montserrat; Viladot, Margarita; Font, Carme; Aya, Francisco; Vidal Losada, Maria Jesús; Caballero, Rosalía; Carrasco, Eva; Altomare, Vittorio; Tonini, Giuseppe; Prat Aparicio, Aleix; Martín, Miguel |
18-Sep-2019 | Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial | Adamo, Barbara; Bellet Ezquerra, Meritxell; Paré, Laia; Pascual, Tomás; Vidal Losada, Maria Jesús; Pérez Fidalgo, José A.; Blanch, Salvador; Martínez, Noelia; Murillo, Laura; Gómez Pardo, Patricia; López González, Ana; Amillano, Kepa; Canes, Jordi; Galván, Patricia; Gonzalez Farré, Blanca; Gonzalez, Xavier; Villagrasa, Patricia; Ciruelos, Eva; Prat Aparicio, Aleix |
25-Sep-2019 | PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution | Pernas, Sònia; Petit, Anna; Climent, Fina; Paré, Laia; Perez Martin, J.; Ventura, Luz; Bergamino Sirvén, Milana; Galván, Patricia; Falo, Catalina; Morilla, Idoia; Fernandez Ortega, Adela; Stradella, Stradella; Rey, Montse; Garcia Tejedor, Amparo; Gil Gil, Miguel; Prat Aparicio, Aleix |
20-Jan-2020 | Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade | Brasó Maristany, Fara; Griguolo, Gaia; Pascual, Tomás; Paré, Laia; Nuciforo, Paolo; Llombart Cussac, Antonio; Bermejo de las Heras, Begoña; Oliveira, Mafalda; Morales, Serafín; Martínez, Noelia; Vidal Losada, Maria Jesús; Adamo, Barbara; Martínez, Olga; Pernas, Sònia; López, Rafael; Muñoz Mateu, Montserrat; Chic, Núria; Galván, Patricia; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, Eduardo; Gregorio, Sara; Gomis, Roger R.; Villagrasa, Patricia; Cortés, Javier; Ciruelos, Eva; Prat Aparicio, Aleix |
May-2017 | Resistance to taxanes in triple negative breast cancer associates with the dynamics of a CD49f+ tumor initiating population | Gómez Miragaya, Jorge; Palafox Sánchez, Marta; Paré, Laia; Yoldi, Guillermo; Ferrer, Irene; Vila, Sergi; Galván, Patricia; Pellegrini, Pasquale; Pérez-Montoyo, Hector; Igea, Ana; Muñoz Moruno, Purificación; Esteller, Manel; Nebreda, Àngel R.; Urruticoechea Ribate, Ander; Morilla, Idoia; Pernas, Sònia; Climent, Fina; Soler, María Teresa; Petit, Anna; Serra, Violeta; Prat Aparicio, Aleix; González Suárez, Eva |
18-Dec-2015 | Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. | Prat Aparicio, Aleix; Fan, Cheng; Fernández Martínez, Aranzazu; Hoadley, Katherine A.; Martinello, Rossella; Vidal Losada, Maria Jesús; Viladot, Margarita; Pineda, Estela; Arance, Ana; Muñoz Mateu, Montserrat; Paré, Laia; Cheang, Maggie C. U.; Adamo, Barbara; Perou, Charles M. |
9-Jan-2019 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial | Gavilá, Joaquín; Oliveira, Mafalda; Pascual, Tomás; Perez-Garcia, Jose; Gonzàlez, Xavier; Canes, Jordi; Paré, Laia; Calvo Serrano, Isabel; Ciruelos, Eva; Muñoz Mateu, Montserrat; Virizuela, Juan A.; Ruiz, Isabel; Andrés, Raquel; Perelló, Antonia; Martínez, Jerónimo; Morales, Serafín; Marín Aguilera, Mercedes; Martínez, Debora; Quero, Juan C.; Llombart-Cussac, Antonio; Prat Aparicio, Aleix |
23-Apr-2021 | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer | Pascual, Tomás; Oliveira, Mafalda; Ciruelos, Eva; Bellet Ezquerra, Meritxell; Saura, Cristina; Gavilá, Joaquin; Pernas, Sònia; Muñoz Mateu, Montserrat; Vidal Losada, Maria Jesús; Margelí Vila, Mireia; Cejalvo Andújar, Juan Miguel; González Farré, Blanca; Espinosa Bravo, Martin; Cruz, Josefina; Salvador Bofill, Francisco Javier; Guerra, Juan Antonio; Luna Barrera, Ana María; Arumi de Dios, Miriam; Esker, Stephen; Fan, Pang-dian; Martínez Sáez, Olga; Villacampa, Guillermo; Paré, Laia; Ferrero Cafiero, Juan M.; Villagrasa, Patricia; Prat Aparicio, Aleix |
1-Oct-2019 | The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models | Gómez Miragaya, Jorge; Moran, Sebastian; Calleja Cervantes, Maria E.; Collado-Solé, Alejandro; Paré, Laia; Gómez, Antonio; Serra, Violeta; Dobrolecki, Lacey E.; Lewis, Michael T.; Diaz-Lagares, Angel; Eroles, Pilar; Prat Aparicio, Aleix; Esteller, Manel; González Suárez, Eva |